Title
Category
Credits
Event date
Cost
  • PAINWeek
  • 20.00 AANP
  • 20.00 ACCME (All Other)
  • 20.00 ACCME (MD/DO Only)
  • 20.00 ACPE Pharmacy
  • 20.00 ANCC
  • 20.00 APA
$1,500.00
  • LivDerm
  • TME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
$0.00
Hidradenitis suppurativa (HS), also called acne inversa, is an inflammatory disease characterized by recurring, painful abscesses, and fistulous tracts, and can impact adults and pediatric patients. Symptoms of HS include pain and scarring as well as psychological consequences, such as embarrassment, social isolation, and depression, and is associated with a poor quality of life. Several studies suggest that the prevalence of HS ranges from 0.00033 to 4.1%, although underdiagnosis or improper diagnosis is an issue. 
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development and FDA-approval of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Moreover, these vital healthcare providers need education on disease pathophysiology, burden, and the impact this illness imparts on the whole patient.
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), and despite a higher HF symptom burden, they are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future.
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Atrial fibrillation (AF) remains underdiagnosed, particularly in African American patients with a high burden of AF risk factors, such as those with cardiometabolic comorbidities. Additionally, stroke prevention in these patients is suboptimal, with suboptimal application of evidence-based therapies and guidelines, including the suboptimal use of direct oral anticoagulants (DOACs).
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Pediatric patients with skin of color (SOC) face unique challenges in managing AD, including issues with disease associated sequelae. In fact, these patients are more likely to suffer from more severe AD cases. It has also been observed that patients with darker pigmented skin are more likely to develop hypo or hyperpigmentation at the affected sites of disease, and these effects often remain long after the symptoms have gone.
  • CMHC
  • 2.00 ABIM MOC and AMA PRA Category 1 Credit
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit
  • 2.00 ANCC
  • 2.00 CDE
  • 2.00 Participation
$0.00
Non-alcoholic steatohepatitis (NASH) is a metabolic-based constellation of multiple organ pathology that overlaps with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. The sequelae of NASH, stemming from nonalcoholic fatty liver disease (NAFLD), has at the root of it, several of these cardiometabolic risk factors and existing cardiovascular disease.
  • LivDerm
  • TME
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
$0.00
The treatment of AD is a clinical challenge on a global level. Targeted immunomodulatory agents, based on recent advances in the understanding of the disease pathophysiology, represent additional options for long-term control.
  • CMHC
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
$0.00
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that clinicians face in reducing the burden of anemia in patients with CKD.
  • PAINWeek
  • 0.50 AANP
  • 0.50 ACCME (All Other)
  • 0.50 ACCME (MD/DO Only)
  • 0.50 ACPE Pharmacy
  • 0.50 ANCC
$0.00
As the opioid crises continues to loom over the landscape of pain management, there is a growing interest among practitioners for alternative analgesia and delivery systems. As such, topical and transdermal therapeutic options are being utilized with greater frequency among pain practitioners. This presentation will address the advantages that topical analgesics have over systemically administered analgesics, including the ability to provide effective analgesia with reduced systemic drug levels, a factor particularly beneficial to the elderly.

Pages